1. Executive Summary (Confidence: High)

Juvion Life Sciences is a high-potential spin-off from EPFL, founded in 2024 to tackle the "mobility crisis" of an aging global population. The company utilizes a proprietary in vivo screening platform that merges AI, machine vision, and robotics to identify naturally derived compounds that stabilize the motor system. Their lead product candidate, JUV-001—a plant-derived supplement—has shown substantial improvements in mobility during preclinical trials and is slated for market entry in early 2026. With $639K in initial funding and recognition as a "Venture Leader Biotech," Juvion is positioned as a first-in-class player in the "Geroscience" space, focusing on a biological mechanism (neuron-muscle communication) that has been largely overlooked by traditional pharmaceutical developers.